ArticleArchives of medical sciences. Atherosclerotic diseases2026
Therapeutic role of low-volume plasma exchange in modulating lipopolysaccharides-binding protein and inflammatory pathways in metabolic syndrome.
Article in Archives of medical sciences. Atherosclerotic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Metabolic syndrome (MetSy) is associated with chronic low-grade inflammation and metabolic dysfunction, contributing to increased cardiometabolic risk. Low-volume plasma exchange (LVPE) is an emerging extracorporeal therapy designed to reduce systemic inflammation by removing circulating pro-inflammatory mediators. This study evaluated the effects of LVPE on metabolic endotoxemia, inflammation, and mineral metabolism in individuals with MetSy. Material and methods: A total of 48 adults with MetSy were enrolled, including 33 men and 15 women, with an average age of 50 years (men: 51 years; women: 48 years). All participants met established diagnostic criteria for MetSy. Each underwent four LVPE cycles using nanoporous membranes designed to selectively remove pro-inflammatory mediators while preserving essential plasma components. Biomarkers of systemic inflammation (CRP, hsCRP), endotoxemia (LBP, zonulin), and mineral metabolism (zinc, magnesium, iron) were measured before and after treatment. Results: LVPE significantly reduced CRP levels ( Conclusions: Four cycles of LVPE effectively reduced low-grade inflammation, as indicated by decreased CRP levels, supporting its potential role as a therapeutic approach in managing inflammation in MetSy. Its effects on endotoxemia and gut permeability remain inconclusive, underscoring the need for additional research to clarify long-term and mechanistic outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.